Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. It is a leader in understanding the role of the Transforming Growth Factor-Beta, or TGF-Beta, family of proteins, which are master regulators of red blood cell and platelet production as well as of the growth, repair and maintenance of muscle and bone. It has leveraged this understanding and developed a discovery approach to generate large and small molecules to address diseases of these tissues. Targeting TGF-Beta signaling pathways has been clinically proven to elicit robust changes in blood cells, muscle and bone, which it believe provides a precedent and strong rationale for its strategy. Its lead protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. It has observed positive topline results in a Phase 1 clinical trial of KER-050, and it plan to initiate two Phase 2 clinical trials, one in patients with MDS and one in patients with myelofibrosis. Its lead small molecule product candidate, KER-047, is being developed for the treatment of anemia resulting from elevated levels of hepcidin, the key regulator of iron absorption and recycling, as well as for the treatment of fibrodysplasia ossificans progressiva, or FOP, a rare musculoskeletal disorder, and is currently in a Phase 1 clinical trial. Its third product candidate, KER-012, is being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or PAH. It plan to progress KER-012 into a Phase 1 clinical trial in the second half of 2021.